{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T01:59:59Z","timestamp":1785635999159,"version":"3.56.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.semarthrit.2017.04.005","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T06:45:40Z","timestamp":1493102740000},"page":"343-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis"],"prefix":"10.1016","volume":"47","author":[{"given":"Atul","family":"Deodhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.04.005_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.rdc.2012.09.003","article-title":"Epidemiology of spondyloarthritis","volume":"38","author":"Stolwijk","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/13543784.2014.899351","article-title":"Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis","volume":"23","author":"Braun","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib6","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","article-title":"Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy","volume":"12","author":"Rudwaleit","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-016-0969-2","article-title":"Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort","volume":"18","author":"Ciurea","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib8","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3899\/jrheum.150389","article-title":"Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study","volume":"42","author":"Heinonen","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/rheumatology\/kev001","article-title":"Drug survival of anti-tumour necrosis factor alpha therapy in spondyloarthropathies: results from the Spanish emAR II Study","volume":"54","author":"Rosales-Alexander","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib10","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","article-title":"Switching tumour necrosis factor \u03b1 antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period","volume":"66","author":"Conti","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib12","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2014-205490","article-title":"First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register","volume":"73","author":"Lie","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib13","first-page":"958","article-title":"Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA","volume":"27","author":"Pavelka","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.5414\/CP201707","article-title":"The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009\u2014a retrospective analysis","volume":"50","author":"Nell-Duxneuner","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"issue":"S6","key":"10.1016\/j.semarthrit.2017.04.005_bib16","first-page":"007","article-title":"Treatment patterns and costs for anti-TNF\u03b1 therapy in patients with ankylosing spondylitis","volume":"S6","author":"Palmer","year":"2015","journal-title":"Rheumatology (Sunnyvale)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib17","doi-asserted-by":"crossref","DOI":"10.3904\/kjim.2016.042","article-title":"Drug survival of tumor necrosis factor \u03b1 inhibitors in patients with ankylosing spondylitis in Korea","author":"Jeong","year":"2016","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","article-title":"Efficacy in current practice of switching between anti-tumour necrosis factor- \u03b1 agents in spondyloarthropathies","volume":"50","author":"Paccou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib19","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.3899\/jrheum.150372","article-title":"Tumor necrosis factor-\u03b1 inhibition in ankylosing spondylitis and nonradiographic axial spondyloarthritis: treatment response, drug Survival, and patient outcome","volume":"42","author":"Corli","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib20","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/rheumatology\/ket249","article-title":"Remission in ankylosing spondylitis treated with anti-TNF-\u03b1 drugs: a national multicentre study","volume":"52","author":"Spadaro","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib21","doi-asserted-by":"crossref","first-page":"e0131864","DOI":"10.1371\/journal.pone.0131864","article-title":"Predictors of switching anti-tumor necrosis factor therapy in patients with ankylosing spondylitis","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib22","doi-asserted-by":"crossref","first-page":"862969","DOI":"10.1155\/2014\/862969","article-title":"Drug retention rates and treatment discontinuation among anti-TNF-\u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice","volume":"2014","author":"Fabbroni","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib23","first-page":"1010","article-title":"Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients","volume":"29","author":"Dadoun","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2017.04.005_bib24","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1007\/s10198-014-0598-0","article-title":"Real-life experience with switching TNF-\u03b1 inhibitors in ankylosing spondylitis","volume":"15","author":"Gulyas","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","article-title":"Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis","volume":"47","author":"Coates","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib26","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/ken334","article-title":"Switching anti-TNF therapy in ankylosing spondylitis","volume":"47","author":"Pradeep","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib27","first-page":"857","article-title":"Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scir\u00e8","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor \u03b1 drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib29","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10067-015-2929-7","article-title":"Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL","volume":"34","author":"Faf\u00e1","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","article-title":"Ten years with biologics: to whom do data on effectiveness and safety apply?","volume":"50","author":"Simard","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib32","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib33","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.141278","article-title":"Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials","volume":"42","author":"Baraliakos","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib34","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/acr.20258","article-title":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register","volume":"62","author":"Kristensen","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib35","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","article-title":"Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis","volume":"51","author":"Baraliakos","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","article-title":"Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib38","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2011-200828","article-title":"Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab","volume":"71","author":"Plasencia","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","article-title":"Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment","volume":"58","author":"Breban","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib41","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","article-title":"The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study","volume":"74","author":"Lie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib42","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/art.39691","article-title":"The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial spondyloarthritis","volume":"68","author":"Nissen","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib43","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/art.39772","article-title":"Effect of comedication with conventional synthetic disease-modifying antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with spondyloarthritis: a prospective cohort study","volume":"68","author":"Sepriano","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.rdc.2012.08.004","article-title":"Therapeutic controversies: tumor necrosis factor \u03b1 inhibitors in ankylosing spondylitis","volume":"38","author":"Song","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib45","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3899\/jrheum.141000","article-title":"2014 Update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada","volume":"42","author":"Rohekar","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib46","unstructured":"2014 ACR\/SAA\/SPARTAN recommendations for the management of axial spondyloarthritis, including ankylosing spondylitis, and children with the enthesitis-related arthritis form of juvenile idiopathic arthritis. Project plan. http:\/\/www.rheumatology.org\/Portals\/0\/Files\/Axial%20SpA%20Project%20Plan.pdf [accessed August 30, 2016]."},{"key":"10.1016\/j.semarthrit.2017.04.005_bib47","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3899\/jrheum.141001","article-title":"2014 Update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. part II: specific management recommendations","volume":"42","author":"Rohekar","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib49","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib50","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"75","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.04.005_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23233","article-title":"Secukinumab sustains improvement in signs and symptoms of patients with active ankylosing spondylitis through 2 years: Results from a phase 3 study","author":"Marzo-Ortega","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217301117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217301117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T10:56:44Z","timestamp":1535885804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217301117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0049017217301117"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.04.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}